IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

20 January 2022 Gilead Sciences has sued an array of pharmaceutical suppliers and distributors accusing them of forming a ...

Jefferies biotech analyst Michael Yee joins Market Domination to lay out his bull case on Gilead (GILD) and how investors should consider their biotech positions relative to the GLP-1 weight-loss ...

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...

Jefferies biotech analyst Michael Yee joins Market Domination to lay out his bull case on Gilead (GILD) and how investors should consider their biotech positions relative to the GLP-1 weight-loss ...

Jefferies biotech analyst Michael Yee joins Market Domination to lay out his bull case on Gilead (GILD) and how investors should consider their biotech positions relative to the GLP-1 weight-loss ...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...

Researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients. This discovery has fueled new strategies that ...

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other ...

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the ...